Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Exclusion Criteria

• •Have received an investigational agent or used an investigational device within 28 days of the first dose of study drug.
• •Have expected to require any other form of systemic or localized antineoplastic therapy while on study.
• •Have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.).
• •History of severe hypersensitivity reaction to any monoclonal antibody.
• •History of encephalitis, meningitis, dementia, Parkinson's or uncontrolled seizures within 1 year prior to the first dose of study drug.
• •Uncontrolled infection of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), or Tuberculosis.
• •Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft.
• •Patient has a pulse oximetry of \<92% on room air.
• •Patient is on supplemental home oxygen.
• •Has clinically significant heart disease.
• •Conditions, including alcohol or drug dependence that would affect the patient's ability to comply with study visits and procedures.
• •Patient is pregnant or breastfeeding.
• •Unwilling or unable to follow the study schedule for any reason.
• •Patient received a live vaccine within 30 days of planned start of study medication.
• •Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.